Stocks
Sionna Therapeutics, Inc.SION
NASDAQHealthcareBiotechnology$3.60
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing small molecule therapies targeting cystic fibrosis, with a lead program aimed at correcting the underlying defect in the CFTR protein. The company went public in 2024 and is closely watched for its differentiated approach to CF treatment, which could offer an alternative to existing modulator therapies. Investors track SION for its pipeline progress and potential to capture a significant share of the cystic fibrosis market.
52W Range: $3.55-$54.97
Congressional Interest in Sionna Therapeutics, Inc. (SION)
No congressional trades have been disclosed for Sionna Therapeutics, Inc. (SION) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SION?
No congressional trades found for this stock.